Search
Omburtamab
go.drugbank.com/drugs/DB15635Investigational[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.
Oxytocin
go.drugbank.com/drugs/DB00107ApprovedInvestigationalVet approved[A229108] Oxytocin continues to be an important tool in modern obstetrics to induce labor when indicated and to manage postpartum hemorrhage. … [A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work.
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor … [A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeZolmitriptan
go.drugbank.com/drugs/DB00315ApprovedInvestigationalZolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine. … [A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsCRx-119
go.drugbank.com/drugs/DB05688ExperimentalCRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of … CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine.
Hypercholesterolemia, Autosomal Dominant
go.drugbank.com/conditions/DBCOND0037437Synonyms: LDL receptor disorder, LDL - Low density lipoprotein receptor disorderZuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalThis compound belongs to the thioxanthenes. … Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsTetrofosmin
go.drugbank.com/drugs/DB11180ApprovedTetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. … Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.[A7788]
Neon
go.drugbank.com/drugs/DB11589ApprovedIt is the fifth most abundant chemical element in the universe by mass but a rare element on Earth. … Neon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test.
Mixtures: Co-NE-O2-N2 Mixture, Lung Diffusion Test Mix No Ne CoSynonyms: NeCitalopram
go.drugbank.com/drugs/DB00215ApprovedInvestigationalCitalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. … [A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Antagonists